Live tape
Top 8, mentions 7d7,637NVDA1,345 mentions▲ +0.09GOOGL1,166 mentions▲ +0.04AVGO1,034 mentions▲ +0.05NKE1,030 mentions+0.01LULU964 mentions▲ +0.03TSLA923 mentions▲ +0.06META634 mentions▲ +0.05QQQ541 mentions▲ +0.08

Equity · Healthcare

PRGO

Perrigo Company plc · NYSE

$10.72 −2.55% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$12 $9 10 Jun 17 Jul

The line runs $11.17 on 10 June through $10.72 on 17 July, on a scale from $9 to $12. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of PRGO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $11.17 on 10 June 2026 through $10.72 on 17 July 2026.

Market cap $1.5B
52-week range $9.24 – $28.10
Avg volume 781.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

PRGO insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 8 Jul 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 8

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Jul 2026 Khoury Roberto EVP and President of CSCI Option exercise 737 $8K
08 Jul 2026 Khoury Roberto EVP and President of CSCI Tax withheld 385 $4K
08 Jul 2026 Winterman Matthew John EVP, Supply, Ops, Strategy Option exercise 17,503 $184K
08 Jul 2026 Winterman Matthew John EVP, Supply, Ops, Strategy Tax withheld 9,138 $96K
12 Jun 2026 Alford Bradley A Director Option exercise 976 $11K
12 Jun 2026 Alford Bradley A Director Tax withheld 469 $5K
12 Jun 2026 Parker Geoffrey M. Director Option exercise 976 $11K
12 Jun 2026 Parker Geoffrey M. Director Tax withheld 469 $5K

PRGO reported financials

SEC EDGAR XBRL

PRGO reported revenue of $4.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$1.4B.

Figure Reported Period
Revenue $4.3B 31 Dec 2025 fiscal year
Net income −$1.4B 31 Dec 2025 fiscal year
Diluted EPS −$10.29 31 Dec 2025 fiscal year
Total assets $7.6B 27 Jun 2026 at period end
Total equity $2.5B 27 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 27 Jun 2026

PRGO earnings

SEC EDGAR
Date Period EPS Revenue
27 Jun 2026 Q2 2026 $0.53 —
28 Mar 2026 Q1 2026 $-2.87 —
31 Dec 2025 FY 2025 $-10.29 —
27 Sep 2025 Q3 2025 $0.05 —
28 Jun 2025 Q2 2025 $-0.06 —
29 Mar 2025 Q1 2025 $-0.05 —
31 Dec 2024 FY 2024 $-1.25 —
28 Sep 2024 Q3 2024 $-0.15 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PRGO institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a PRGO position for the quarter ended 30 Jun 2026 — a combined $117.0M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Added +409.8% shares 3,480,666 $35.3M
Millennium Management Trimmed −30.3% shares 2,982,331 $31.0M
Man Group Added +55.2% shares 1,530,206 $15.9M
GAMCO Investors Held (±25%) −2.4% shares 1,363,707 $14.2M
Point72 Asset Management New position 713,173 $7.4M
Maverick Capital New position 448,053 $4.7M
Bridgewater Associates Added +158.5% shares 324,076 $3.4M
Citadel Advisors Trimmed −90.2% shares 199,776 $2.1M
Two Sigma Investments Held (±25%) −15.4% shares 124,021 $1.3M
D. E. Shaw & Co. Trimmed −68.8% shares 108,619 $1.1M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

PRGO fails-to-deliver

SEC CNS data

On 14 Aug 2026, 3,615 shares of PRGO failed to deliver (about $46K).

Settlement date Shares failed Notional % of shares out
14 Aug 2026 3,615 $46K 0.003%
11 Aug 2026 155 $2K <0.001%
06 Aug 2026 932 $12K 0.001%
28 Jul 2026 2,941 $30K 0.002%
27 Jul 2026 5,770 $58K 0.004%

Source: SEC fails-to-deliver (CNS) data